A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores-Reference-Cited by-同舟云学术

A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores

Published:2021-06 Issue: Volume: Page:
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

De Vincentis Antonio,Tavaglione Federica,Jamialahmadi Oveis,Picardi Antonio,Antonelli Incalzi Raffaele,Valenti Luca,Romeo Stefano,Vespasiani-Gentilucci Umberto

Funder

Airc Italian Foundation for Cancer Research

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Novo Nordisk Fonden

AstraZeneca plc

Svenska Diabetesstiftelsen

European Commission

Stiftelsen för strategisk forskning

Swedish Governmental Agency for Innovation Systems

Ministero della Salute

Knut Och Alice Wallenbergs Stiftelse

Vetenskapsradet

Hjärt-lungfonden

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Non-alcoholic fatty liver disease – a global public health perspective;Younossi;J Hepatol,2019

2. Non-alcoholic fatty liver disease and steatohepatitis: state of the art on effective therapeutics based on the gold standard method for diagnosis;Mahjoubin-Tehran;Mol Metab,2020

3. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies;Pimpin;J Hepatol,2018

4. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease;Angulo;Gastroenterology,2015

5. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C;Wai;Hepatology,2003

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies;Metabolism;2024-12

2. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

3. Dietary patterns in the progression of metabolic dysfunction-associated fatty liver disease to advanced liver disease: a prospective cohort study;The American Journal of Clinical Nutrition;2024-09

4. Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases;Journal of Hepatology;2024-08

5. What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives;International Journal of Molecular Sciences;2024-07-15